A key target of SDG3 is to reduce premature mortality from non-communicable diseases (target 3.4), specifically in relation to mortality rates attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease (3.4.1) by 2030.
Journal of Translational Medicine contributes to the global efforts of researchers and clinicians to meet this target by publishing high-quality articles across several expert-led sections such as Cancer Microenvironment, Combination Strategies, Immune RadioBiology, and Translational Cancer Biology.
In 2023, the launch of the Fibrosis section, focusing on the normal and pathogenetic processes of tissue repair, led to the Fibrosis and Cancer Intersection (FACI) article collection. With research implicating fibrosis in the proliferation and migration of cancer cells, the collection was timely and has garnered over 40,000 article accesses.
Guest Editors Dr Mary Salvatore (Vice Chair of Education for Department of Radiology at Columbia University) and Dr Monica Pernia (Columbia University) expressed their objective for the collection in an Editorial:
“The improved understanding of how fibrosis develops, causes morbidity, and promotes cancer is the foundation for making advances in diagnosis, treatment, and ultimately prevention.”
This year's theme for World Cancer Day (4th February), "United by unique", highlights how every experience with cancer is unique. Hence, the FACI article collection is particularly topical in demonstrating this through the discussion of different types of cancers (breast cancer, lung cancer, ovarian cancer, pancreatic cancer, and prostate cancer), the systems affected (thoracic, abdominal, and genitourinary organs), and the treatments involved (immunotherapy, radiotherapy and other therapeutic interventions).
In line with SDG3 target 3.4, the Guest Editors explain that a collection like Fibrosis and Cancer Intersection which is aimed at “increasing the understanding of the relationship between fibrosis and cancer development would be of great benefit for the medical scientific community since this knowledge could accelerate the development of new therapies to treat cancer while increasing the hostility of the cancer cells’ microenvironment by preventing or interfering with collagen deposition. This evidence could explain the development of tumoral resistance to immune defenses and existing or emergent anti-cancer therapies.”
We invite you to check out the Fibrosis and Cancer Intersection article collection!